Medarex to Present at the Bank of America 2007 Health Care Conference
Posted on: Thursday, 24 May 2007, 06:00 CDT
PRINCETON, N.J., May 24 /PRNewswire-FirstCall/ -- Medarex, Inc. announced today that it is scheduled to present at the Bank of America 2007 Health Care Conference at 6:20 PM Eastern Time on Thursday, May 31, 2007. The conference is being held at The Four Seasons Hotel in Las Vegas, Nevada. Medarex's presentation will be webcast live and will be available for replay through the Webcasts page in the Investor Relations section of the Medarex website via the Internet at http://www.medarex.com/.
Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 30 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with six of the most advanced product candidates currently in Phase III clinical trials. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com/.
Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.
Medarex, Inc.
CONTACT: Laura S. Choi, Investor Relations, x2216, or Jean Mantuano,Corporate Communications, media, x2221, both of Medarex, Inc., +1-609-430-2880
Web site: http://www.medarex.com/
Company News On-Call: http://www.prnewswire.com/comp/108265.html
Source: PRNewswire-FirstCall
Related Articles
- Amarillo Biosciences to Support Western Australian Government Sponsored Human Influenza Clinical Trial in Perth, Australia
- Galapagos Announces Pre-Clinical Candidates and Clinical Plans in Rheumatoid Arthritis and Bone Metastasis
- Affitech Moves to Further Strengthen Human Antibody Intellectual Property Position
- Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported By Peregrine
- Ono and Medarex Enter Into Second Collaboration for the Development of a Fully Human Antibody Therapeutic
- Array BioPharma Achieves Milestone for Selection of Second Clinical Candidate for MEK Anti-Cancer Program
- Acceptys, Inc. And OncoMab GmbH Announce Integration of Human Antibody Drug Development Pipeline and Operations
- Medarex and Massachusetts Biologic Laboratories Announce Commencement of Phase II Clinical Trial of a Fully Human Antibody for the Treatment of Hospital Acquired Diarrhea
- Medarex Announces Agreement to License UltiMAb Human Antibody Development System(R) to ImClone Systems
- THP Generates Transgenic Rabbits Producing Human Antibodies
 |
 |
User Comments (0)
RSS Feeds